Miyako Capital has contributed to a series A round for the cancer vaccine developer, which expanded to Japan last year.

VLP Therapeutics, a US-based cancer vaccine developer, secured $15m yesterday in a series A round that included Miyako Capital, a venture capital vehicle for Kyoto University. Chemicals producer Konishiyasu and diversified conglomerate Sojitz also participated in the round, as did SK Impact Fund, RJ Fund and private investor Robert Hisaoka, all three of which were…

The rest of this content is only accessible to University Venturing: News, Data, and Events - Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.